174 related articles for article (PubMed ID: 19420015)
1. alpha-Tocopheryl succinate and derivatives mediate the transcriptional repression of androgen receptor in prostate cancer cells by targeting the PP2A-JNK-Sp1-signaling axis.
Huang PH; Wang D; Chuang HC; Wei S; Kulp SK; Chen CS
Carcinogenesis; 2009 Jul; 30(7):1125-31. PubMed ID: 19420015
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma-independent suppression of androgen receptor expression by troglitazone mechanism and pharmacologic exploitation.
Yang CC; Wang YC; Wei S; Lin LF; Chen CS; Lee CC; Lin CC; Chen CS
Cancer Res; 2007 Apr; 67(7):3229-38. PubMed ID: 17409431
[TBL] [Abstract][Full Text] [Related]
3. PP2A inhibitors arrest G2/M transition through JNK/Sp1- dependent down-regulation of CDK1 and autophagy-dependent up-regulation of p21.
Gong FR; Wu MY; Shen M; Zhi Q; Xu ZK; Wang R; Wang WJ; Zong Y; Li ZL; Wu Y; Zhou BP; Chen K; Tao M; Li W
Oncotarget; 2015 Jul; 6(21):18469-83. PubMed ID: 26053095
[TBL] [Abstract][Full Text] [Related]
4. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
5. Suppression of the androgen receptor function by quercetin through protein-protein interactions of Sp1, c-Jun, and the androgen receptor in human prostate cancer cells.
Yuan H; Young CY; Tian Y; Liu Z; Zhang M; Lou H
Mol Cell Biochem; 2010 Jun; 339(1-2):253-62. PubMed ID: 20148354
[TBL] [Abstract][Full Text] [Related]
6. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Bhardwaj A; Singh S; Srivastava SK; Honkanen RE; Reed E; Singh AP
Mol Cancer Ther; 2011 May; 10(5):720-31. PubMed ID: 21393425
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S
Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160
[TBL] [Abstract][Full Text] [Related]
8. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
[TBL] [Abstract][Full Text] [Related]
9. Repression of androgen receptor in prostate cancer cells by phenethyl isothiocyanate.
Wang LG; Liu XM; Chiao JW
Carcinogenesis; 2006 Oct; 27(10):2124-32. PubMed ID: 16704988
[TBL] [Abstract][Full Text] [Related]
10. Stress kinase signaling regulates androgen receptor phosphorylation, transcription, and localization.
Gioeli D; Black BE; Gordon V; Spencer A; Kesler CT; Eblen ST; Paschal BM; Weber MJ
Mol Endocrinol; 2006 Mar; 20(3):503-15. PubMed ID: 16282370
[TBL] [Abstract][Full Text] [Related]
11. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
12. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression.
Verras M; Lee J; Xue H; Li TH; Wang Y; Sun Z
Cancer Res; 2007 Feb; 67(3):967-75. PubMed ID: 17283128
[TBL] [Abstract][Full Text] [Related]
13. Vitamin E succinate inhibits the function of androgen receptor and the expression of prostate-specific antigen in prostate cancer cells.
Zhang Y; Ni J; Messing EM; Chang E; Yang CR; Yeh S
Proc Natl Acad Sci U S A; 2002 May; 99(11):7408-13. PubMed ID: 12032296
[TBL] [Abstract][Full Text] [Related]
14. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells.
Yuan H; Gong A; Young CY
Carcinogenesis; 2005 Apr; 26(4):793-801. PubMed ID: 15661808
[TBL] [Abstract][Full Text] [Related]
15. Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.
Deng X; Shao G; Zhang HT; Li C; Zhang D; Cheng L; Elzey BD; Pili R; Ratliff TL; Huang J; Hu CD
Oncogene; 2017 Mar; 36(9):1223-1231. PubMed ID: 27546619
[TBL] [Abstract][Full Text] [Related]
16. Dephosphorylation of Sp1 at Ser-59 by protein phosphatase 2A (PP2A) is required for induction of CYP1A1 transcription after treatment with 2,3,7,8-tetrachlorodibenzo-p-dioxin or omeprazole.
Shimoyama S; Kasai S; Kahn-Perlès B; Kikuchi H
Biochim Biophys Acta; 2014 Feb; 1839(2):107-15. PubMed ID: 24382322
[TBL] [Abstract][Full Text] [Related]
17. PP2A regulates upstream members of the c-jun N-terminal kinase mitogen-activated protein kinase signaling pathway.
Zhao B; Sun L; Haas M; Denenberg AG; Wong HR; Shanley TP
Shock; 2008 Feb; 29(2):181-8. PubMed ID: 17693927
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor induces EPHA3 expression by interacting with transcription factor SP1.
Diao X; Chen X; Pi Y; Zhang Y; Wang F; Liu P; Gao Y; Wang X; Yang S; Lu S
Oncol Rep; 2018 Aug; 40(2):1174-1184. PubMed ID: 29917167
[TBL] [Abstract][Full Text] [Related]
19. Growth of the pancreatic cancer cell line PANC-1 is inhibited by protein phosphatase 2A inhibitors through overactivation of the c-Jun N-terminal kinase pathway.
Li W; Chen Z; Gong FR; Zong Y; Chen K; Li DM; Yin H; Duan WM; Miao Y; Tao M; Han X; Xu ZK
Eur J Cancer; 2011 Nov; 47(17):2654-64. PubMed ID: 21958460
[TBL] [Abstract][Full Text] [Related]
20. Critical roles for JNK, c-Jun, and Fas/FasL-Signaling in vitamin E analog-induced apoptosis in human prostate cancer cells.
Jia L; Yu W; Wang P; Li J; Sanders BG; Kline K
Prostate; 2008 Mar; 68(4):427-41. PubMed ID: 18196534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
